Search

The patients reported that treatment with Cal/BD aerosol foam was "very good" in terms of effectiveness (64.5%), tolerability (59.0%), ease of application (58.8%) and overall treatment satisfaction (64.3%) (Fig. GLO:3NZ/01dec21:jdv17593-fig-0001.jpg PHOTO (COLOR): 1 Satisfaction with previous psoriasis treatments assessed at study enrolment (baseline) and with Cal/BD aerosol foam treatment at the end of week 4. Patient-reported outcomes with calcipotriol/betamethasone aerosol foam in patients with plaque psoriasis in Greece. [Extracted from the article]

Background: Apremilast is an oral phosphodiesterase‐4 inhibitor indicated for patients with moderate‐to‐severe chronic plaque psoriasis and active psoriatic arthritis. Objectives: To examine the effectiveness of apremilast on Dermatology Life Quality Index (DLQI), Psoriasis Area and Severity Index (PASI) and nail, scalp and palmoplantar involvement, when administered prior to biologics. Methods: This 52‐week real‐world study included biologic‐naive adults with moderate psoriasis (psoriasis‐involved body surface area 10% to <20%, or PASI 10 to <20 and DLQI 10 to <20). Apremilast was initiated ≤7 days before enrolment. Data from the first 100 eligible patients who completed 24 weeks (W24) of observation (or were prematurely withdrawn) are presented in this interim analysis using the last‐observation‐carried‐forward imputation method. Results: Eligible patients (mean age: 49.9 years; 71.0% males; median disease duration: 8.0 years) were consecutively enrolled between April and October 2017, by 18 dermatology specialists practising in hospital outpatient settings in Greece. Baseline DLQI (median: 12.0) and PASI (median: 11.7) scores improved (P < 0.001) at all postbaseline timepoints (Weeks 6, 16 and 24; W24 median decreases: 9.0 and 9.4 points respectively). At W24, DLQI ≤5, DLQI 0 or 1, and PASI‐75 response rates were 63.0%, 25.0% and 48.0% respectively. The Nail Psoriasis Severity Index score in patients with baseline nail involvement (n = 57) decreased at all postbaseline timepoints (P < 0.001; W24 median decrease: 20.0 points). At W24, 50.0% and 51.7% of patients with baseline scalp (n = 76) and palmoplantar (n = 29) involvement respectively achieved postbaseline Physician's Global Assessment (PGA) score of 0 or 1 if baseline score was ≥3, or 0 if baseline score was 1 or 2. The adverse drug reaction rate was 21.0% (serious: 2.0%). Conclusions: These interim results indicate that through 24 weeks, apremilast improved quality of life and reduced disease severity in biologic‐naive patients with moderate plaque psoriasis, while demonstrating safety consistent with the known safety profile. [ABSTRACT FROM AUTHOR]

Fixed combination aerosol foam calcipotriene 0.005% (Cal) plus betamethasone dipropionate 0.064% (BD) is more efficacious than Cal or BD aerosol foam alone for psoriasis vulgaris: a randomized, double-blind, multicenter, three-arm, phase 2 study. Plaque psoriasis (psoriasis) is a chronic, immune-mediated inflammatory disorder, with a prevalence of approximately 2% in Europe and North America.1 Psoriasis is classified as mild, moderate and severe,2 while ~70-80% of patients suffer from mild disease.1 The European S3 Guidelines recommend the use of vitamin D3 derivatives and steroids combination for the first four weeks as induction therapy.2 An innovative Calcipotriol/Betamethasone (Cal/BD) fixed combination aerosol foam formulation has been developed to enhance adherence in the topical treatment.3 This study aimed to provide real-world data on the effectiveness of Cal/BD aerosol foam in treated patients with at least mild psoriasis. Superior efficacy of calcipotriene and betamethasone dipropionate aerosol foam versus ointment in patients with psoriasis vulgaris-a randomized phase II study. [Extracted from the article]

European patient perspectives on the impact of psoriasis: the EUROPSO patient membership survey. When the low may still be high: the heavy burden of residual psoriasis in difficult-to-treat areas despite a low DLQI score among patients under biologics or apremilast: a 5-year, prospective, case-control study A total of 318 patients [172 patients with residual psoriasis in difficult-to-treat areas (study group); 146 patients as control group] were included in the analysis. [Extracted from the article]

Psoriasis constitutes a chronic inflammatory disease that affects 0.5-3% of the population with a serious negative impact on patients' quality of life.1 Beyond its correlation with known cardiovascular risk factors, psoriasis is considered an independent risk factor for atherosclerosis and subsequent cardiovascular events. Concerning CAD complexity, patients with SYNTAX score <=22 were classified as low-complexity CAD, while those with SYNTAX >=23 and SYNTAX >=33 as intermediate and high CAD complexity, respectively 4. Additional studies are warranted to confirm the causality between psoriasis severity and CAD complexity with the potential to facilitate interdisciplinary risk stratification and improve patient outcomes. [Extracted from the article]